Bausch Health (BHC)
(Delayed Data from NYSE)
$10.49 USD
+0.63 (6.39%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $10.54 +0.05 (0.48%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.49 USD
+0.63 (6.39%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $10.54 +0.05 (0.48%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
Why Earnings Season Could Be Great for Bausch Health (BHC)
by Zacks Equity Research
Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Humana (HUM) Gears Up for Q3 Earnings: What Awaits the Stock?
by Zacks Equity Research
Humana's (HUM) third-quarter 2020 results are likely to reflect elevated expenses and lower net investment income, partially offset by a growing membership base.
Universal Health (UHS) to Report Q3 Results: What to Expect
by Zacks Equity Research
Universal Health's (UHS) third-quarter earnings results are likely to reflect depressed revenues and weak admissions.
Centene's (CNC) Q3 Earnings Improve Y/Y on High Revenues
by Zacks Equity Research
Centene's (CNC) third-quarter results reflect higher revenues and managed care membership.
Anthem (ANTM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem's (ANTM) third-quarter earnings results are likely to reflect elevated costs and a softness in Commercial business line.
Bausch Acquires License for Myopia Solution from Eyenovia
by Zacks Equity Research
Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.
Bausch (BHC) Down 19.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch (BHC) Q2 Earnings & Revenues Miss Estimates, Down Y/Y
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the second quarter and announces plans to spin off its eye care division.
Bausch Health (BHC) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -28.79% and -8.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Bausch Health (BHC) Might Surprise This Earnings Season
by Zacks Equity Research
Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Humana (HUM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) Q2 results are likely to reflect better revenues and membership growth.
Earnings Preview: Bausch Health (BHC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch (BHC) Up 21.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch (BHC) Down on Q1 Earnings & Sales Miss, View Trimmed
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the first quarter and lowers guidance due to the coronavirus pandemic.
Endo (ENDP) Q1 Earnings Beat on Coronavirus-Led Stockpiling
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the first quarter owing to increased customer inventory purchasing due to the COVID-19 pandemic
Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -1.11% and -1.68%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Bausch Health (BHC) Ahead of Earnings?
by Zacks Equity Research
Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bausch Health (BHC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm Starts Dosing With Selinexor for Coronavirus Infection
by Zacks Equity Research
Karyopharm (KPTI) doses the first patient in a phase II study evaluating the low dose of its drug Xpovio (selinexor) to treat hospitalized patients with severe COVID-19 infection. Shares up.
Bausch (BHC) Starts Study on Virazole for Coronavirus Infection
by Zacks Equity Research
Bausch (BHC) begins a clinical study on Virazole in combination with standard-of-care therapy to treat adults with respiratory distress due to COVID-19 in Canada.
Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak
by Zacks Equity Research
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
Why Is Bausch (BHC) Down 46.5% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Aerie (AERI) reports a wider loss in the fourth quarter, while sales surpass expectations.
Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.
Should You Buy Bausch Health (BHC) Ahead of Earnings?
by Zacks Equity Research
Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.